Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Gastrointestinal 5Tumor-Agnostic 3CNS 2Thoracic 1Genitourinary 1

Conditions

Neoplasm Metastasis 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × trastuzumab deruxtecan × Genitourinary × Clear all
NCT03523572 2025-01-27

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Daiichi Sankyo

Phase 1 Completed
86 enrolled 22 charts
BreastGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡